---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-169077"
form_type: "8-K"
ticker: "CLYM"
cik: "0001768446"
company_name: "Climb Bio, Inc."
filed_at: "2024-06-26T23:59:59+00:00"
generated_at: "2026-06-01T01:43:00.441363+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Shareholders approve Eliem-Tenet merger; closing expected June 27, 2024

## Summary
- Share Issuance Proposal passed: 26,311,239 for, 3,253 against; disinterested approval 12,655,083 for.
- Directors Andrew Levin and Liam Ratcliffe elected to board until 2027.
- PricewaterhouseCoopers ratified as independent auditor for FY2024.
- Acquisition of Tenet Medicines and concurrent PIPE expected to close on or about June 27, 2024.

## SEC filing metadata
- accession: 0001193125-24-169077
- form_type: 8-K
- ticker: CLYM
- cik: 0001768446
- company_name: Climb Bio, Inc.
- filed_at: 2024-06-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 5.07, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768446/000119312524169077/0001193125-24-169077-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768446/000119312524169077/d788381d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-169077
- JSON: https://secwatch.observer/filing/0001193125-24-169077.json
- Plain text: https://secwatch.observer/filing/0001193125-24-169077.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.